Parosmia Tied to Smell Recovery After Olfactory Training
THURSDAY, Dec. 3, 2020 -- For patients with postinfectious smell loss receiving olfactory training, the presence of parosmia is associated with clinically relevant recovery in olfactory discrimination and identification function, according to a study published online Nov. 19 in The Laryngoscope.
David T. Liu, M.D., from the Technical University of Dresden in Germany, and colleagues conducted a retrospective cohort study involving 143 adults with postinfectious smell loss who received olfactory training. The authors examined the association between smell loss-related factors and clinically relevant changes in overall and subdimensional olfactory function of threshold, discrimination, and identification.
The researchers found that those with lower baseline olfactory function were more likely to have clinically relevant improvements in overall olfactory function. Those with lower baseline olfactory function and those with parosmia at the initial visit were more likely to have relevant improvements in discrimination function; they were also more likely to have relevant improvement in odor identification. Those who were older in age were more likely to have clinically significant improvements in odor threshold.
"We found that the presence of parosmia and worse smell performance on testing of odor identification and discrimination was associated with clinically significant recovery in smell function for people experiencing postviral smell disorders," a coauthor said in a statement. "This means that smell training can help the smell pathways to start to regenerate and recover."
© 2021 HealthDay. All rights reserved.
Posted: December 2020
Read this next
FRIDAY, Jan. 22, 2021 -- Treatment with bamlanivimab and etesevimab, but not monotherapy with bamlanivimab, is associated with a reduction in severe acute respiratory syndrome...
FRIDAY, Jan. 22, 2021 -- There was a decrease in the total number of pediatric emergency department visits in 2020, but the proportion of trauma-related visits increased,...
THURSDAY, Jan. 21, 2021 -- Tocilizumab plus standard care is not superior to standard care alone for improving clinical outcomes among patients with severe or critical COVID-19...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.